European Heart Journal

This article reviews the most relevant literature published in 2021 on the role of cardiovascular imaging in cardiovascular medicine. Coronavirus disease 2019 (COVID-19) continued to impact the healthcare landscape, resulting in reduced access to hospital-based cardiovascular care including reduced routine diagnostic cardiovascular testing. However, imaging has also facilitated the understanding of the presence and extent of myocardial damage caused by the coronavirus infection. What has dominated the imaging literature beyond the pandemic are novel data on valvular heart disease, the increasing use of artificial intelligence (AI) applied to imaging, and the use of advanced imaging modalities in both ischaemic heart disease and cardiac amyloidosis.

خرید پکیج و مشاهده آنلاین مقاله

Nudging within learning health systems: next generation decision support to improve cardiovascular care

Yang Chen, Steve Harris, Yvonne Rogers, Tariq Ahmad, Folkert W. Asselbergs

doi : 10.1093/eurheartj/ehac030

European Heart Journal, Volume 43, Issue 13, 1 April 2022, Pages 1296â€“1306

The increasing volume and richness of healthcare data collected during routine clinical practice have not yet translated into significant numbers of actionable insights that have systematically improved patient outcomes. An evidence-practice gap continues to exist in healthcare. We contest that this gap can be reduced by assessing the use of nudge theory as part of clinical decision support systems (CDSS). Deploying nudges to modify clinician behaviour and improve adherence to guideline-directed therapy represents an underused tool in bridging the evidence-practice gap. In conjunction with electronic health records (EHRs) and newer devices including artificial intelligence algorithms that are increasingly integrated within learning health systems, nudges such as CDSS alerts should be iteratively tested for all stakeholders involved in health decision-making: clinicians, researchers, and patients alike. Not only could they improve the implementation of known evidence, but the true value of nudging could lie in areas where traditional randomized controlled trials are lacking, and where clinical equipoise and variation dominate. The opportunity to test CDSS nudge alerts and their ability to standardize behaviour in the face of uncertainty may generate novel insights and improve patient outcomes in areas of clinical practice currently without a robust evidence base.

خرید پکیج و مشاهده آنلاین مقاله

Five-year outcomes after state-of-the-art percutaneous coronary revascularization in patients with de novo three-vessel disease: final results of the SYNTAX II study

Adrian P Banning, Patrick Serruys, Giovanni Luigi De Maria, Nicola Ryan, Simon Walsh, Nieves Gonzalo, Robert Jan van Geuns, Yoshinobu Onuma, Manel Sabate, Justin Davies, Maciej Lesiak, Raul Moreno, Ignacio Cruz-Gonzalez, Stephen P Hoole, Jan J Piek, Clare Appleby, Farzin Fath-Ordoubadi, Azfar Zaman, Nicolas M Van Mieghem, Neal Uren, Javier Zueco, Pawel Buszman, Andres Iniguez, Javier Goicolea, David Hildick-Smith, Andrzej Ochala, Dariusz Dudek, Ton de Vries, David Taggart, Vasim Farooq, Ernest Spitzer, Jan Tijssen, Javier Escaned

doi : 10.1093/eurheartj/ehab703

European Heart Journal, Volume 43, Issue 13, 1 April 2022, Pages 1307â€“1316

The SYNTAX II study evaluated the impact of advances in percutaneous coronary intervention (PCI), integrated into a single revascularization strategy, on outcomes of patients with de novo three-vessel disease. The study employed decision-making utilizing the SYNTAX score II, use of coronary physiology, thin-strut biodegradable polymer drug-eluting stents, intravascular ultrasound, enhanced treatments of chronic total occlusions, and optimized medical therapy. Patients treated with this approach were compared with predefined patients from the SYNTAX I trial.

خرید پکیج و مشاهده آنلاین مقاله

â€˜State of the Artâ€™ PCI: bridging the implementation gap

Zaid I Almarzooq, Robert W Yeh

doi : 10.1093/eurheartj/ehab855

European Heart Journal, Volume 43, Issue 13, 1 April 2022, Pages 1317â€“1319

â€˜State of the Artâ€™ PCI: strategies used, outcomes, and future directions. PCI, percutaneous coronary intervention; IVUS, intravascular ultrasound; OCT, optical coherence tomography; iFR, instantaneous wave-free ratio; FFR, fractional flow reserve; CTO, chronic total occlusion; CAD, coronary artery disease; DES, drug-eluting stent, MACCE, major adverse cardiac and cerebrovascular events; MI, myocardial infarction.

خرید پکیج و مشاهده آنلاین مقاله

Amphilimus- vs. zotarolimus-eluting stents in patients with diabetes mellitus and coronary artery disease: the SUGAR trial

Rafael Romaguera, Pablo Salinas, Josep Gomez-Lara, Salvatore Brugaletta, Antonio GÃ³mez-Menchero, Miguel A Romero, Sergio GarcÃa-Blas, Raymundo Ocaranza, Pascual Bordes, Marcelo JimÃ©nez Kockar, Neus Salvatella, Victor A JimÃ©nez-DÃaz, Mar Alameda, Ramiro Trillo, Dae Hyun Lee, Pedro MartÃn, MarÃa LÃ³pez-Benito, Alfonso Freites, Virginia Pascual-Tejerina, Felipe HernÃ¡ndez-HernÃ¡ndez, Bruno GarcÃa del Blanco, Mohsen Mohandes, Francisco Bosa, Eduardo Pinar, Gerard Roura, Josep Comin-Colet, Antonio FernÃ¡ndez-Ortiz, Carlos Macaya, Xavier Rossello, Manel Sabate, Stuart J Pocock, Joan A GÃ³mez-Hospital, SUGAR trial investigators

doi : 10.1093/eurheartj/ehab790

European Heart Journal, Volume 43, Issue 13, 1 April 2022, Pages 1320â€“1330

Patients with diabetes mellitus are at high risk of adverse events after percutaneous revascularization, with no differences in outcomes between most contemporary drug-eluting stents. The Cre8 EVO stent releases a formulation of sirolimus with an amphiphilic carrier from laser-dug wells, and has shown clinical benefits in diabetes. We aimed to compare Cre8 EVO stents to Resolute Onyx stents (a contemporary polymer-based zotarolimus-eluting stent) in patients with diabetes.

خرید پکیج و مشاهده آنلاین مقاله

Amphilimus-eluting stents in coronary artery disease: finally, a sweet spot for patients with diabetes mellitus?

Robert A. Byrne, Himanshu Rai, RÃ³isÃn Colleran

doi : 10.1093/eurheartj/ehab894

European Heart Journal, Volume 43, Issue 13, 1 April 2022, Pages 1331â€“1333

خرید پکیج و مشاهده آنلاین مقاله

Single or multiple arterial bypass graft surgery vs. percutaneous coronary intervention in patients with three-vessel or left main coronary artery disease

Piroze M Davierwala, Chao Gao, Daniel J F M Thuijs, Rutao Wang, Hironori Hara, Masafumi Ono, Thilo Noack, Scot Garg, Neil O'leary, Milan Milojevic, Arie Pieter Kappetein, Marie-Claude Morice, Michael J Mack, Robert-Jan van Geuns, David R Holmes, Jr, Mario Gaudino, David P Taggart, Yoshinobu Onuma, Friedrich Wilhelm Mohr, Patrick W Serruys, for the SYNTAX Extended Survival Investigators

doi : 10.1093/eurheartj/ehab537

European Heart Journal, Volume 43, Issue 13, 1 April 2022, Pages 1334â€“1344

The aim of this study was to compare long-term all-cause mortality between patients receiving percutaneous coronary intervention (PCI) and coronary artery bypass grafting (CABG) using multiple (MAG) or single arterial grafting (SAG).

خرید پکیج و مشاهده آنلاین مقاله

The optimal strategy for multivessel coronary revascularization

Joanna Chikwe, Ottavio R Alfieri

doi : 10.1093/eurheartj/ehab768

European Heart Journal, Volume 43, Issue 13, 1 April 2022, Pages 1345â€“1347

خرید پکیج و مشاهده آنلاین مقاله

Cost-effectiveness analysis of left atrial appendage occlusion in patients with atrial fibrillation and contraindication to oral anticoagulation

Frida Labori, Josefine Persson, Carl Bonander, Katarina Jood, Mikael Svensson

doi : 10.1093/eurheartj/ehab847

European Heart Journal, Volume 43, Issue 13, 1 April 2022, Pages 1348â€“1356

This study aims to estimate the cost-effectiveness of percutaneous left atrial appendage occlusion (LAAO) compared to standard stroke prevention care for patients with atrial fibrillation (AF) and contraindication to oral anticoagulation (OAC) in a Swedish healthcare and public sector perspective.

خرید پکیج و مشاهده آنلاین مقاله